PharmaEngine (4162) — Cash Flow Reinvestment Rate
PharmaEngine (4162) has a Cash Flow Reinvestment Rate of 8.59x as of September 2025, reinvesting NT$455.53 Million (capex NT$115.00K plus investments NT$-455.41 Million) from operating cash flow of NT$53.01 Million. See PharmaEngine free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
PharmaEngine Cash Flow Reinvestment Rate (2011–2024)
Historical reinvestment intensity for PharmaEngine across 12 annual periods. For the full cash flow conversion analysis, see 4162 cash flow metrics.
Annual Cash Flow Reinvestment Rate for PharmaEngine (2011–2024)
Year-by-year capital reinvestment analysis for PharmaEngine. See financial flexibility index of PharmaEngine to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.25x | NT$116.09 Million | NT$456.73 Million | NT$1.42 Million | ▼ -92.4% |
| 2023 | 3.33x | NT$856.44 Million | NT$256.97 Million | NT$958.00K | ▲ +258.3% |
| 2022 | 0.93x | NT$187.92 Million | NT$202.01 Million | NT$3.94 Million | ▲ +721.8% |
| 2021 | 0.11x | NT$105.23 Million | NT$929.67 Million | NT$229.00K | ▼ -99.6% |
| 2020 | 27.26x | NT$1.77 Billion | NT$64.77 Million | NT$608.00K | ▲ +2267.7% |
| 2019 | 1.15x | NT$18.51 Million | NT$16.08 Million | NT$208.00K | ▲ +42.4% |
| 2018 | 0.81x | NT$602.36 Million | NT$745.23 Million | NT$510.00K | ▲ +8.1% |
| 2016 | 0.75x | NT$650.89 Million | NT$870.38 Million | NT$1.15 Million | ▼ -87.7% |
| 2015 | 6.10x | NT$2.73 Billion | NT$447.99 Million | NT$11.80 Million | ▲ +841249.6% |
| 2014 | 0.00x | NT$95.00K | NT$131.09 Million | NT$95.00K | ▼ -40.1% |
| 2012 | 0.00x | NT$83.00K | NT$68.64 Million | NT$83.00K | ▼ -58.7% |
| 2011 | 0.00x | NT$806.00K | NT$275.49 Million | NT$806.00K | — |